For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Semaglutide
Illustration for Semaglutide

THE PEPSRADAR ENCYCLOPEDIA

Semaglutide

Incretin signaling and appetite regulation

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Semaglutide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (OZEMPIC) on DailyMed ↗

Compare: Semaglutide vs Tirzepatide

What is Semaglutide?

Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.

Video overview · 3:02

Semaglutide: What the Trials Actually Show (Ozempic, Wegovy and Rybelsus Explained)

How it copies the gut hormone GLP-1, what the STEP, SELECT and FLOW trials found for weight, heart and kidney outcomes, the side effects and label warnings, the trials still under way, and its FDA approvals.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

Semaglutide is the medicine in Ozempic, Wegovy and Rybelsus, approved for type 2 diabetes, weight management, heart and kidney risk in certain people, and a form of fatty liver disease. It has been tested in trials with thousands of people. Here is what they actually show.

Semaglutide is a lab-made version of GLP-1, a gut hormone involved in appetite and blood sugar, built to last much longer in the body than the natural hormone. It boosts insulin when blood sugar is high, slows stomach emptying, and reduces appetite. How it protects the kidneys has not been worked out.

In STEP 1, nearly two thousand adults with obesity but no diabetes lost about fifteen percent of their weight on average over sixty-eight weeks, versus about two percent on placebo. In SELECT, over seventeen thousand people with heart disease and excess weight had a twenty percent lower risk of heart attack, stroke or heart-related death. In FLOW, people with diabetes and kidney disease had a twenty-four percent lower risk of serious kidney outcomes or heart or kidney death.

The most common side effects are digestive, like nausea, vomiting, diarrhea and constipation. The labels warn about pancreatitis and gallbladder disease, and in the SUSTAIN-6 diabetes trial, eye complications were more common than on placebo. There is also a boxed warning: semaglutide caused thyroid tumors in rodents, and whether it does in humans is unknown.

More answers are coming. The liver trial behind Wegovy's fatty liver approval is continuing for about four and a half years, to see whether semaglutide keeps people free of cirrhosis. Another trial is tracking diabetic eye disease over five years, with results expected in 2027.

Semaglutide is FDA approved. Ozempic was approved in 2017 for type 2 diabetes, and later to lower heart and kidney risks in some people with diabetes. Rybelsus is a tablet for diabetes. Wegovy is approved for weight management, heart-risk reduction and a form of fatty liver disease. Compounded copies are not FDA approved, and the FDA has warned sellers of so-called research versions.

Do Ozempic and Wegovy contain the same drug? Yes, both are semaglutide, approved for different uses. Does the weight stay off after stopping? In STEP 4, people switched to placebo regained much of what they had lost. And is research-labeled semaglutide the real drug? PepsRadar's claim check says that is not supported. Tested online products have shown low purity, and the FDA warns that counterfeit Ozempic has been found in the US.

The bottom line: semaglutide is an approved medicine with strong evidence for weight loss, and for heart and kidney benefits in specific groups, plus common digestive side effects. For every study and source, see the semaglutide profile on PepsRadar dot com.

Biological role or research focus

Incretin signaling and appetite regulation.

Brand, formulation, and indication matter. An approved product does not validate a research-use-only version.

Role reference: MedlinePlus: Semaglutide injection ↗

Names you may encounter

Ozempic · Wegovy · Rybelsus

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
GLP-1 receptor agonist
Main research area
Metabolic and indication-specific outcomes
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus: Semaglutide injection ↗

Quick answers

Is Semaglutide FDA approved?
Yes. Ozempic (NDA 209637, 2017) for type 2 diabetes, with later approvals to lower heart risk (2020) and kidney-disease worsening and heart-related death (January 2025) in adults with type 2 diabetes. Source ↗
Is Semaglutide safe?
Semaglutide is a widely used GLP-1 drug; stomach side effects are common, and the label warns of thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease and diabetic eye complications. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Semaglutide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Semaglutide?
Yes. Our records list 4 FDA actions naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

4 Human research
StudyTypePopulation / model
STEP 1 (2021)Human randomized trial1,961 adults with obesity, or overweight with a weight-related condition, without diabetes.
FLOW kidney outcomes (2024)Human randomized trial3,533 adults with type 2 diabetes and chronic kidney disease.
SELECT cardiovascular outcomes (2023)Human randomized trial17,604 adults aged 45 or older with established cardiovascular disease, BMI at least 27, and no history of diabetes.
STEP 4 · continuation versus withdrawal (2021)Human randomized withdrawal trial803 adults without diabetes who completed a 20-week semaglutide run-in and reached the studied maintenance regimen; 902 initially entered run-in.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2021

STEP 1

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Population / model
1,961 adults with obesity, or overweight with a weight-related condition, without diabetes.
Study design
Semaglutide versus placebo for 68 weeks, alongside lifestyle intervention.
Main finding
Mean weight change was −14.9% versus −2.4%, a 12.4-percentage-point estimated difference. Gastrointestinal effects were common.
Limits & context
These are average results for a specific injectable regimen and trial population. The study is not a comparison with tirzepatide and cannot validate compounded or research-use products.

Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗

Human randomized trial · 2024

FLOW kidney outcomes

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

Population / model
3,533 adults with type 2 diabetes and chronic kidney disease.
Study design
Randomized placebo-controlled trial of once-weekly injected semaglutide; stopped early at a prespecified interim analysis because of benefit, after a median 3.4 years.
Main finding
Major kidney disease events (kidney failure, a fall in kidney function of at least half, or death from kidney or cardiovascular causes) were 24% lower with semaglutide (hazard ratio 0.76). Death from cardiovascular causes and from any cause were also lower, and serious adverse events were slightly less common (49.6% vs 53.8%).
Limits & context
Applies to people with type 2 diabetes and established kidney disease. Trials stopped early for benefit can overstate the effect, and the trial says nothing about people without diabetes or about research-use products.

Source: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes ↗

Human randomized trial · 2023

SELECT cardiovascular outcomes

Did treatment affect cardiovascular events in people without diabetes?

Population / model
17,604 adults aged 45 or older with established cardiovascular disease, BMI at least 27, and no history of diabetes.
Study design
Double-blind placebo-controlled trial of the studied semaglutide formulation; mean follow-up 39.8 months.
Main finding
Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. Hazard ratio 0.80 (95% CI 0.72–0.90). Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%.
How to read it
The observed event proportions differ by 1.5 percentage points. The hazard ratio describes relative event rates over follow-up; it is not a 20-percentage-point absolute reduction.
Limits & context
This population already had cardiovascular disease. The result does not establish the same benefit in every person seeking weight loss or validate unregulated preparations. Funded by Novo Nordisk.

Source: Lincoff et al. · NEJM · SELECT · 2023 ↗

Human randomized withdrawal trial · 2021

STEP 4 · continuation versus withdrawal

What happened after continuing treatment or switching to placebo?

Population / model
803 adults without diabetes who completed a 20-week semaglutide run-in and reached the studied maintenance regimen; 902 initially entered run-in.
Study design
Double-blind randomized withdrawal comparison over a further 48 weeks, with lifestyle intervention in both groups.
Main finding
From randomization at week 20 to week 68, weight changed by −7.9% with continued semaglutide versus +6.9% after switching to placebo. Gastrointestinal events occurred in 49.1% versus 26.1%.
How to read it
These changes start at randomization, after the initial run-in loss. They are not percentages measured from the original baseline.
Limits & context
People unable to reach the regimen during run-in were not randomized. This selected population limits generalization to everyone starting treatment. It is not a trial of tapering or an individualized stopping strategy.

Source: Rubino et al. · JAMA · STEP 4 · 2021 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

80 registered studies name Semaglutide as an intervention among the 100 most recently updated of 811 search results; 44 are recruiting or under way, 18 have not started recruiting yet and 18 completed. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
A Study of BGM0504 in Participants With Type 2 Diabetes
NCT06716216 · BrightGene Bio-Medical Technology Co., Ltd.
CompletedPhase 32025-01-13553
Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults
NCT07935200 · Korea United Pharm. Inc.
Not yet recruitingPhase 12027-01-0144
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
NCT06745284 · Boehringer Ingelheim
Active, not recruitingPhase 12025-03-2664
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
NCT07642635 · Vanderbilt University Medical Center
RecruitingPhase 1 / Phase 22026-1230
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599 · Novo Nordisk A/S
Not yet recruitingPhase 32026-11-101060
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872 · Hoffmann-La Roche
RecruitingPhase 22025-08-19330
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573 · Novo Nordisk A/S
Not yet recruitingPhase 32026-11-101200
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098 · Regeneron Pharmaceuticals
CompletedPhase 22024-03-131005

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 80 listed studies.

Search additional PubMed records ↗

Risks & interactions

Semaglutide is a widely used GLP-1 drug; stomach side effects are common, and the label warns of thyroid C-cell tumors in rodents, pancreatitis, gallbladder disease and diabetic eye complications.

FDA boxed warning

Caused thyroid C-cell tumors in rodents; it is unknown whether it does in humans. Do not use with a personal or family history of medullary thyroid carcinoma or with MEN 2.

Human safety data: FDA label

Safety is established by FDA labeling and large trials. This entry summarizes the Ozempic label; other semaglutide products have their own labels. Whether the rodent thyroid tumors matter for humans is unknown, and pregnancy data are limited.

Take extra care with: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problems

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Serious allergy to semaglutide or any ingredient
  • Severe gastroparesis (very slow stomach emptying): not recommended
  • Pregnancy, when used for weight loss (Wegovy): no benefit and possible fetal harm, and the label says to stop when pregnancy is recognized

Interactions

  • Insulin or sulfonylureas: higher risk of low blood sugar, including severe episodes
  • Oral medicines: slowed stomach emptying may change how they are absorbed

Serious risks

  • Acute pancreatitis
  • Worsening diabetic eye disease (retinopathy)
  • Kidney injury from dehydration
  • Severe stomach and bowel side effects
  • Gallbladder disease
  • Serious allergic reactions, and inhaling stomach contents during anesthesia or deep sedation

Common side effects

  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • constipation

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Ozempic (semaglutide) prescribing information ↗ · Wegovy prescribing information (DailyMed) ↗

Side effects by the numbers: how common are they?

In STEP 1 (1,961 adults without diabetes, 68 weeks), stomach and gut side effects were reported by 74.2% of people on semaglutide versus 47.9% on placebo. On semaglutide, 44.2% reported nausea, 31.5% diarrhea, 24.8% vomiting and 23.4% constipation. Most were mild to moderate and eased over time, but 4.5% stopped treatment because of them, versus 0.8% on placebo. Gallbladder problems, mostly gallstones, affected 2.6% versus 1.2%.

Source: Wilding et al. · NEJM · STEP 1 · 2021 ↗

The 2026 vision warning (NAION)

In November 2026 the FDA required all GLP-1 medicines, semaglutide included, to warn about NAION, a rare optic-nerve condition that causes sudden, painless vision loss in one eye. Across 126 trials it occurred 6.4 times per 100,000 person-years on GLP-1 medicines versus 3.8 on comparators, based on 15 cases in all. Sudden vision loss, blind spots or blurring in one eye need a same-day call to a health care professional. The NAION article under Research guides below has the full numbers.

Source: FDA Drug Safety Communication: GLP-1 receptor agonists and NAION (November 2026) ↗

Key precautions

Gastrointestinal effects, dehydration, gallbladder and pancreatic problems, retinopathy considerations, and thyroid-tumor warnings require review. Other glucose-lowering medicines can alter hypoglycemia risk.

Source: MedlinePlus: Semaglutide injection ↗

Regulatory status

U.S. FDA approval
Approved
Ozempic (NDA 209637, 2017) for type 2 diabetes, with later approvals to lower heart risk (2020) and kidney-disease worsening and heart-related death (January 2025) in adults with type 2 diabetes; Rybelsus tablets (NDA 213182, 2019) for type 2 diabetes; Wegovy injection (NDA 215256, 2021) for weight management, cardiovascular risk reduction and MASH; Wegovy tablets (NDA 218316) approved December 22, 2025. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not prohibited. Semaglutide markers are on WADA's 2026 Monitoring Program (tracked for misuse patterns, not banned). source

FDA actions

  • FDA proposed excluding semaglutide (with tirzepatide and liraglutide) from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk. (2026-04-30) source
  • FDA statement announcing intent to restrict GLP-1 APIs used in mass-marketed non-approved compounded drugs and to act on misleading marketing. (2026-02-06) source
  • FDA page on risks of unapproved and compounded GLP-1 drugs, including dosing errors, fraudulent products and "research use only" sellers (updated October 1, 2026). (2026-10-01) source
  • FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source

Other notes

  • Semaglutide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
  • WADA 2026 Monitoring Program includes markers of semaglutide (in and out of competition). source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

The current injection reference includes selected diabetes, weight-management, cardiovascular, kidney, and noncirrhotic MASH contexts. Eligibility and approval attach to the exact product and population; this is not a single unrestricted indication.

Source: MedlinePlus: Semaglutide injection ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).

Mechanism & research rationale

It supports glucose-dependent insulin release, slows stomach emptying, and affects appetite. Separate trials are needed to establish weight, cardiovascular, kidney, or liver outcomes.

Source: MedlinePlus: Semaglutide injection ↗

Molecular structure

Semaglutide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 56843331 ↗

Questions worth asking

  • Which exact product is being discussed?
  • Is a podcast describing a study, an approved indication, or a personal experience?
  • Brand, formulation, and indication matter. An approved product does not validate a research-use-only version.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

What are the dangers of semaglutide?

The common problems are stomach and gut side effects: in STEP 1, 74.2% on semaglutide reported them versus 47.9% on placebo, and 4.5% stopped treatment because of them. Less common risks on the label include gallbladder problems, pancreatitis and dehydration, and the FDA added a warning in 2026 about NAION, a rare cause of sudden vision loss in one eye. The label also carries a boxed warning about thyroid C-cell tumors seen in rodents, with human relevance unknown. These risks are weighed against proven benefits such as fewer heart attacks and strokes in SELECT.

Source: Wilding et al. · NEJM · STEP 1 · 2021 ↗

Is STEP 1 evidence for every semaglutide formulation?

No. It studied a particular injectable regimen and population without diabetes.

Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗

Can its percentage weight loss be ranked directly against another trial?

Different populations and study methods can distort such comparisons. A direct randomized comparison is more informative.

Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗

What does the SELECT cardiovascular outcomes study show, and what does it not?

The observed event proportions differ by 1.5 percentage points. The hazard ratio describes relative event rates over follow-up; it is not a 20-percentage-point absolute reduction. This population already had cardiovascular disease. The result does not establish the same benefit in every person seeking weight loss or validate unregulated preparations. Funded by Novo Nordisk.

Source: Lincoff et al. · NEJM · SELECT · 2023 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

RESEARCH FIELD GUIDE

GLP-1s and keto: a real-food playbook for losing fat, not muscle

A GLP-1 medicine turns down your appetite. What you eat with that smaller appetite decides how much of the weight you lose is fat and how much is muscle. Lived experience and the published research on cutting carbs, ketones, electrolytes, kidney stones, muscle, fasting, real food and sleep, including where the evidence is thin.

Read the guide →

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Semaglutide

Download illustration ↓Source record ↗
Semaglutide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.